Maternal Immunopotentiation Affects Caspase Activation and NF-kappaB DNA-binding Activity in Embryos Responding to an Embryopathic Stress

Effect of maternal immunopotentiation on apoptosis-associated molecules expression in teratogen-treated embryos

PROBLEM

Potentiation of the maternal immune system was shown by us to affect the embryonic response to teratogenic insults. In order to understand better the mechanisms underlying that phenomenon, we explored the effect of maternal immunopotentiation by rat splenocytes on the early stages of the embryonic response to cyclophosphamide (CP).

METHOD OF STUDY

Immunopotentiated CP-treated embryos were analysed for cell cycle changes by flow cytometry, while cell proliferation and apoptosis were assessed by 5'-bromo-2'-deoxyuridine (BrdU) incorporation and terminal deoxynucleotidyl transferase (TdT)-mediated dUTP-biotin nick-end labeling (TUNEL) respectively. The expression of the p65 subunit of NF-kappaB, IkappaBalpha, Bax, bcl-2 and p53 was assessed by flow cytometry.

RESULTS

Exposure to CP resulted in significant growth retardation and in the appearance of cellular damage, a reduction in cell proliferation and the appearance of apoptotic cells, which were all found to be delayed in immunopotentiated embryos. In parallel, CP-treated embryos demonstrated a reduction in the percentage of p65- or IkappaBalpha-positive cells, while the percentage of bcl-2- or p53-positive cells increased initially and decreased later. Those changes were normalized by maternal immunopotentiation when tested at 24 hrs after exposure to the teratogen.

CONCLUSION

Our data implicate maternal immunopotentiation to protect the embryo against teratogenic insults, possibly through its effect on the expression of p65, bcl-2 or p53.

Differential teratogenic response of TNFα+/+ and TNFα−/− mice to cyclophosphamide: The possible role of NF-κB

BACKGROUND

We observed previously that tumor necrosis factor alpha (TNFalpha)-knockout embryos are more sensitive to a cyclophosphamide (CP)-induced teratogenic insult than their TNFalpha-positive counterparts, implicating molecules acting in TNFalpha-activated antiapoptotic pathways in the mechanisms underlying this phenomenon. The main goal of this study was to assess whether the transcription factor nuclear factor kappaB (NF-kappaB) may be 1 of those molecules. Such a choice is based by evidence demonstrating TNFalpha as a powerful activator of NF-kappaB and a key role of the transcription factor in the most effective TNFalpha-activated antiapoptotic cascade. Also, the expression pattern of active caspases 3, 8, and 9 was researched to assess the sensitivity of TNFalpha+/+ and TNFalpha-/- embryos to CP-induced apoptotic stimuli.

METHODS

TNFalpha-knockout mice were exposed to CP on day 12 of pregnancy, with or without an NF-kappaB inhibitor, pyrrolidine dithiocarbamate (PDTC) and sacrificed on day 18 of pregnancy to evaluate the CP-induced teratogenic effect. Embryos harvested 24 or 48 hr after the CP treatment were used to evaluate NF-kappaB DNA-binding and activity of caspases 3, 8, and 9.

RESULTS

PDTC potentiated the CP-induced teratogenic effect and augmented the CP-induced suppression of NF-kappaB DNA-binding. These effects were more prominent in TNFalpha-/- than TNFalpha+/+ embryos. CP-induced caspase activation was found to be similar in TNFalpha-/- and TNFalpha+/+ embryos at 24 hr after treatment. At 48 hr, TNFalpha-/- embryos exhibited higher levels of active caspases 8 and 9 than their TNFalpha-positive counterparts.

CONCLUSIONS

The results of our study allow us to hypothesize that NF-kappaB may be a component of mechanisms underlying differential sensitivity of TNFalpha-/- and TNFalpha+/+ mice to CP-induced teratogenic insult.